0.00Open0.00Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover0.00%IV63.68%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier9DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma18.35Leverage Ratio--Theta--Rho--Eff Leverage--Vega
CVRx Inc Stock Discussion
CVRx Reports Third Quarter 2024 Financial and Operating Results
Positive
▪️Revenue growth of 27% YoY to $13.4 million
▪️U.S. Heart Failure revenue increased 30% to $12.2 million
▪️Active implanting centers grew 31% to 208
▪️Hospital reimbursement increased from $17-23K to $43K per procedure
▪️Secured Category I CPT codes for improved reimbursement
▪️Strong cash position of $100.2 million
▪️Gross margin maintained at 83%
Negative
▪️Net loss increased to $13.1 mil...
CVRx Inc | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Johnson & Johnson(17.0%),Johnson & Johnson Innovation-JJDC, Inc.(17.0%)
📊⚡️📊
CVRx announces new publication reinforcing the long-term quality of life benefits of Barostim
CVRx, Inc. (NASDAQ: CVRX) has announced the publication of new data in JACC: Heart Failure, showcasing the long-term quality of life benefits of Barostim for heart failure patients with reduced ejection fraction. The data, from the BeAT-HF trial, demonstrates durable improvements up to 24 months in Minnesota Living with Heart Failure (MLWHF) and EuroQual-5D (EQ-5D) quality of lif...
No comment yet